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Background: Recent studies have revealed the potential roles of intelectin 1 (ITLN1) in tumorigenesis. However, its
functions and underlying mechanisms in neuroblastoma (NB), the most common extracranial solid tumor in
childhood, still remain largely unknown.
Methods: Human neuroblastoma cell lines were treated with recombinant ITLN1 protein or stably transfected with
ITLN1 expression and short hairpin RNA vectors. Gene expression and signaling pathway were detected by western
blot and real-time quantitative RT-PCR. Gene promoter activity and transcription factor binding were detected by
luciferase reporter and chromatin immunoprecipitation assays. Growth and aggressiveness of tumor cells were
measured by MTT colorimetry, colony formation, scratch assay, matrigel invasion assay, and nude mice model.
Results: Mining of public microarray databases revealed that N-myc downstream regulated gene 2 (NDRG2) was
significantly correlated with ITLN1 in NB. Gain- and loss-of-function studies indicated that secretory ITLN1 facilitated
the NDRG2 expression, resulting in down-regulation of vascular endothelial growth factor (VEGF) and matrix
metalloproteinase 9 (MMP-9), in NB cell lines SH-SY5Y, SK-N-BE(2), and SK-N-SH. Krüppel-like factor 4 (KLF4), a
transcription factor crucial for NDRG2 expression, was up-regulated by ITLN1 in NB cells via inactivation of
phosphoinositide 3-kinase (PI3K)/AKT signaling. Ectopic expression of ITLN1 suppressed the growth, invasion and
metastasis of NB cells in vitro and in vivo. Conversely, knockdown of ITLN1 promoted the growth, invasion, and
metastasis of NB cells. In addition, rescue experiments in ITLN1 over-expressed or silenced NB cells showed that
restoration of NDRG2 expression prevented the tumor cells from ITLN1-mediated changes in these biological
features. In clinical NB tissues, ITLN1 was down-regulated and positively correlated with NDRG2 expression. Patients
with high ITLN1 or NDRG2 expression had greater survival probability.
Conclusions: These findings indicate that ITLN1 functions as a tumor suppressor that affects the growth, invasion
and metastasis of NB through up-regulation of NDRG2.
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Neuroblastoma (NB), the most common extracranial
solid tumor in childhood, accounts for 15% of all
pediatric cancer deaths [1]. For patients with high-risk
NB, despite the application of many therapeutic mo-
dalities, such as surgery, chemoradiotherapy, stem cell
transplantation, and immunotherapy, the prognosis still
remains dismal [1]. Recent evidence indicates that galec-
tins, a family of animal lectins, are aberrantly expressed
in tumor tissues and play crucial roles in neoplastic
transformation and the growth, migration, invasion, and
metastasis of tumor cells [2]. For example, inhibition of
galectin-1 expression significantly suppresses the trans-
formed phenotypes of human glioma cells [3]. Over-
expression of galectin-3 into human T lymphoma Jurkat
cells results in faster growth in vitro [2], while inhibition
of galectin-3 expression attenuates the growth of breast
carcinoma and thyroid papillary carcinoma cells [4,5].
Previous evidence indicates that both galectin-1 and
galectin-7 inhibit the growth of NB cells [6,7], while
galectin-3 is broadly expressed in NB cells to impair the
apoptosis-sensitive phenotype induced by MYCN [8].
However, the roles of other lectins in the progression
and aggressiveness of NB still remain largely unknown
and warrant further investigation.
Intelectin 1 (ITLN1) is a novel identified secretory and
galactose-binding lectin that is expressed in the heart,
small intestine, colon, kidney collecting tubule cells,
bladder umbrella cells, and some mesothelial cells [9,10].
It has been reported that ITLN1 participates in the
immune defense against microorganisms [9], and is
related to chronic obstructive pulmonary disease [11]
and asthma [12]. ITLN1 also participates in insulin-
stimulated glucose uptake in human subcutaneous and
omental adipocytes [13]. More importantly, recent evi-
dence shows the emerging roles of ITLN1 in tumorige-
nesis. ITLN1 is over-expressed in human malignant
pleural mesothelioma (MPM) and secreted into pleural
effusions, and serves as a biomarker for differentiating
from lung cancer [14,15]. Our previous studies have
shown that ITLN1 is aberrantly expressed in gastric
cancer tissues, and is correlated with clinicopathological
features, suggesting its value as a useful prognostic fac-
tor for gastric cancer patients [16]. However, the expres-
sion profiles, exact functions, and downstream targets
of ITLN1 in NB still remain elusive. In the current
study, we demonstrate, for the first time, that ITLN1 is
down-regulated in NB tissues and cell lines. Secretory
ITLN1 suppresses the growth, invasion, and metastasis
of NB cells in vitro and in vivo through up-regulating
N-myc downstream regulated gene 2 (NDRG2). In
addition, the expression of Krüppel-like factor 4 (KLF4),
a transcription factor responsible for the up-regulation
of NDRG2, was enhanced by ITLN1 in NB cells,suggesting the crucial roles of ITLN1 in the progression
and aggressiveness of NB.
Results
ITLN1 facilitates the NDRG2 expression at transcriptional
levels in NB cells
Mining the publicly available clinical tumor expression
datasets [R2: microarray analysis and visualization platform
(http://hgserver1.amc.nl/cgi-bin/r2/main.cgi)] revealed the
decreased ITLN1 transcript levels in some kinds of cancer,
including colon cancer, lung cancer, renal cancer, prostate
cancer, and NB (Additional file 1: Figure S1A). Further
analysis revealed six over-lapping genes significantly corre-
lated with ITLN1 in these cancers (Additional file 1: Figure
S1B), including NDRG2, chaperonin containing TCP1 sub-
unit 3 (CCT3), defective in cullin neddylation 1 domain
containing 5 (DCUN1D5), enolase 1 (ENO1), microtubule-
actin crosslinking factor 1 (MACF1), and Mg2+/Mn2+
dependent protein phosphatase 1G (PPM1G). The ITLN1
and NDRG2 transcript levels in NB tissues were positively
correlated (correlation coefficient R = 0.291, P = 0.0059,
Additional file 1: Figure S1C), and were inversely asso-
ciated with the international neuroblastoma staging system
(INSS) stages (Additional file 1: Figure S1D).
To address the hypothesis that ITLN1 might influence
the NDRG2 expression in NB, recombinant ITLN1 pro-
tein was administrated into cultured NB cell lines SH-
SY5Y and SK-N-BE(2). As shown in Figure 1A, either low
dose (1 μg/ml) or high dose (2 μg/ml) of recombinant
ITLN1 protein markedly induced the expression of
NDRG2 in NB cells at 24 and 36 hrs post-administration.
In addition, ITLN1 vector was stably transfected into SH-
SY5Y and SK-N-BE(2) cells, resulting in enhanced ITLN1
expression and secretion into culture supernatant and in-
creased NDRG2 expression levels, than those stably trans-
fected with empty vector (mock) (Figure 1B and C). In
addition, the expression of vascular endothelial growth
factor (VEGF) and matrix metallopeptidase 9 (MMP-9),
downstream target genes of NDRG2 [17,18], was also
decreased in NB cells treated with recombinant ITLN1
protein or stably transfected with ITLN1 (Figure 1A, B
and C). Since over-expression of NDRG2 suppressed the
expression of VEGF and MMP-9 in NB cells (Additional
file 2: Figure S2A), and knockdown of NDRG2 rescued
ITLN1-induced down-regulation of VEGF and MMP-9
(Additional file 2: Figure S2B), we believed that ITLN1
regulated the expression of VEGF and MMP-9 through
modulating NDRG2. On the other hand, stable tran-
sfection of sh-ITLN1 into SH-SY5Y and SK-N-SH cells re-
sulted in obviously reduced expression and secretion of
ITLN1, decreased NDRG2 levels, and increased expres-
sion of VEGF and MMP-9 than those of scramble short
hairpin RNA (sh-Scb)-transfected cells (Figure 1D and E).














































































































































































































































































































































































































































































































Figure 1 (See legend on next page.)
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Figure 1 ITLN1 facilitates the NDRG2 expression in NB cells. (A) Western blot showing the expression of NDRG2, VEGF, and MMP-9 in solvent
(mock)- or recombinant ITLN1-treated SH-SY5Y (1 and 2 μg/ml, for 24 hrs) and SK-N-BE(2) (1 μg/ml, for 24 and 36 hrs) cells. (B) Western blot
showing the protein levels of ITLN1 [in culture supernatant (s) and lysate], NDRG2, VEGF, and MMP-9 (in lysate) in NB cells stably transfected with
empty vector (mock) or ITLN1. (C) The transcript levels of ITLN1, NDRG2, VEGF, and MMP-9 in NB cells stably transfected with mock or ITLN1 as
measured by real-time quantitative RT-PCR. (D) Western blot showing the expression of ITLN1 [in culture supernatant (s) and lysate], NDRG2, VEGF,
and MMP-9 (in lysate) in SH-SY5Y and SK-N-SH cells stably transfected with sh-Scb or sh-ITLN1. (E) The transcript levels of ITLN1, NDRG2, VEGF, and
MMP-9 in NB cells stably transfected with sh-Scb or sh-ITLN1 as detected by real-time quantitative RT-PCR. (F) Luciferase reporter assay showing
the activity of different NDRG2 promoter fragments in NB cells stably transfected with mock, ITLN1, sh-Scb, or sh-ITLN1. *P < 0.01 vs. mock or sh-Scb.
Li et al. Molecular Cancer  (2015) 14:47 Page 4 of 15ITLN1 resulted in increased and decreased NDRG2
promoter activity in NB cells, respectively, especially
at −395/+192 bp region relative to the transcription start
site (TSS) (Figure 1 F). In contrast, the expression of other
potential target genes analyzed by R2: microarray analysis
and visualization platform, including CCT3, DCUN1D5,
ENO1, MACF1, and PPM1G, was not affected by ITLN1
in NB cells (Additional file 3: Figure S3). Overall, these re-
sults demonstrate that ITLN1 considerably facilitates the
transcription of NDRG2 in NB cells.
Involvement of KLF4 in ITLN1-mediated up-regulation of
NDRG2
To investigate the mechanisms underlying ITLN1-
mediated up-regulation of NDRG2, we analyzed the tran-
scription factor binding sites within NDRG2 promoter,
and noted one potential binding site of transcription
factor KLF4, locating at bases 7–18 upstream the TSS
(Figure 2A). The KLF4 levels were correlated with
NDRG2 expression (correlation coefficient R = 0.441,
P < 0.001) and greater survival probability (P = 0.027) in 88
NB cases derived from R2 microarray analysis and
visualization platform (Additional file 4: Figure S4).
Dual-luciferase assay indicated that ectopic expression or
knockdown of KLF4 increased and decreased the
promoter activity of NDRG2 in NB cells, and the ITLN1-
facilitated NDRG2 promoter activity was abolished by
mutation of KLF4 binding site (Figure 2B). In addition,
chromatin immunoprecipitation (ChIP) and quantitative
PCR (qPCR) indicated that over-expression or knockdown
of ITLN1 increased or decreased the binding of KLF4 on
−133/+55 region of NDRG2 promoter in SH-SY5Y and
SK-N-SH cells, which was rescued by knockdown or ec-
topic expression of KLF4, respectively (Figure 2C). More-
over, western blot and real-time quantitative RT-PCR
indicated that ITLN1 up-regulated the protein levels, but
not the transcript levels, of KLF4 in NB cells (Figure 2D
and E), indicating that ITLN1 may facilitate the expression
of KLF4 at the translational level. Knockdown or ectopic
expression of KLF4 into NB cells prevented the NB cells
from ITLN1-mediated changes in NDRG2 expression
(Figure 2D and E). These results indicate that KLF4 facili-
tates the transcription of NDRG2, and plays a crucial role
in ITLN1-induced up-regulation of NDRG2 in NB cells.ITLN1 facilitates the expression of KLF4 via inactivation of
PI3K/AKT signaling
To further explore the mechanisms for ITLN1-induced
KLF4 expression, we observed the changes in phosphoi-
nositide 3-kinase (PI3K)/AKT signaling that regulates
the KLF4 expression [19]. Administration of recom-
binant ITLN1 protein (1 and 2 μg/ml) into SH-SY5Y
and SK-N-BE(2) cells reduced the phosphorylation of
AKT (T308 and S473), and up-regulated the expression
of KLF4 at 24 and 36 hrs post-administration, than those
treated with solvent control (mock) (Figure 3A). In
contrast, stable knockdown of ITLN1 induced the
phosphorylation of AKT (T308 and S473), and down-
regulated the KLF4 expression in SH-SY5Y and SK-N-
SH cells, which was abolished by administration of PI3K
activity inhibitor LY294002 (Figure 3B). These results
suggest that ITLN1 facilitates the KLF4 expression
through attenuating PI3K/AKT signaling in NB cells.
Ectopic expression of ITLN1 suppresses the growth,
migration and invasion of NB cells through up-regulating
NDRG2
We further investigated the effects of ITLN1 over-
expression and target gene restoration on cultured NB
cells. Transfection of short hairpin RNA (shRNA) target-
ing NDRG2 restored the ITLN1-induced up-regulation
of NDRG2 in SH-SY5Y and SK-N-BE(2) cells (Figure 4A
and Additional file 5: Figure S5A). In line with the
results from MTT colorimetric assay (Additional file 6:
Figure S6A), colony formation assay indicated that
ITLN1 over-expression attenuated the growth of SH-
SY5Y and SK-N-BE(2) cells, when compared to those
stably transfected with empty vector (mock) (Figure 4B
and Additional file 6: Figure S6B). In scratch assay,
ITLN1 over-expression attenuated the migration cap-
abilities of SH-SY5Y and SK-N-BE(2) cells (Figure 4C
and Additional file 6: Figure S6C). Transwell analysis
showed that NB cells stably transfected with ITLN1 pre-
sented an impaired invasion capacity than mock cells
(Figure 4D). In addition, restoration of NDRG2 expres-
sion rescued the NB cells from their changes in these
phenotypes induced by stable over-expression of ITLN1
(Figure 4B, C, and D, Additional file 6: Figure S6A, B,































































































































































































































































































































































































































































































Figure 2 (See legend on next page.)
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Figure 2 Involvement of KLF4 in ITLN1-mediated up-regulation of NDRG2. (A) Scheme of the potential binding site of KLF4 within NDRG2
promoter. (B) Luciferase reporter assay showing the activity of NDRG2 promoter and its mutant in NB cells stably transfected with empty vector
(mock), ITLN1, sh-Scb, or sh-ITLN1, and those co-transfected with sh-KLF4 or KLF4. (C) ChIP and qPCR assays showing the binding of KLF4 on −133/+55
region of NDRG2 promoter in NB cells stably transfected with mock, ITLN1, sh-Scb, or sh-ITLN1, and co-transfected with sh-KLF4 or KLF4. (D) Western
blot showing the protein levels of ITLN1 [in culture supernatant (s)], KLF4, and NDRG2 (in lysate) in NB cells stably transfected with mock, ITLN1, sh-Scb,
or sh-ITLN1, and those co-transfected with sh-KLF4 or KLF4. (E) The transcript levels of ITLN1, KLF4, and NDRG2 in NB cells stably transfected with mock,
ITLN1, sh-Scb, or sh-ITLN1, and those co-transfected with sh-KLF4 or KLF4 as detected by real-time quantitative RT-PCR. *P < 0.01 vs. mock or sh-Scb.
Li et al. Molecular Cancer  (2015) 14:47 Page 6 of 15of ITLN1, and indicate that up-regulation of NDRG2
is involved in the ITLN1-inhibited aggressiveness of
NB cells.
Knockdown of ITLN1 promotes the growth, migration,
and invasion of NB cells in vitro
To further explore the influence of ITLN1 on the ag-
gressiveness of NB cells, we investigated the effects of
ITLN1 knockdown and NDRG2 restoration on cultured
NB cells. Transfection of NDRG2 restored the down-
regulation of NDRG2 induced by ITLN1 knockdown in
SH-SY5Y and SK-N-SH cells (Figure 4E and Additional
file 5: Figure S5B). In MTT colorimetric and colony
formation assays, knockdown of ITLN1 facilitated the
viability and growth of SH-SY5Y and SK-N-SH cells,
than those stably transfected with sh-Scb (Figure 4F,
Additional file 6: Figure S6D and E). In scratch assay,
ITLN1 knockdown increased the migration capabi-
lities of SH-SY5Y and SK-N-SH cells (Figure 4G and

































































Figure 3 ITLN1 facilitates the expression of KLF4 via inactivation of P
AKT (T308 and S473) and expression of KLF4 in solvent (mock)- or recombi
(1 μg/ml for 24 and 36 hrs) cells. (B) Western blot showing the phosphoryl
transfected with sh-Scb or sh-ITLN1, and those pre-treated with LY294002 (that NB cells stably transfected with sh-ITLN1 presented
an increased invasion capacity (Figure 4H). In addition,
restoration of NDRG2 expression rescued the SH-SY5Y
and SK-N-SH cells from their changes in these pheno-
types induced by stable knockdown of ITLN1 (Figure 4F,
G, and H, Additional file 6: Figure S6D, E, and F). These
findings further indicate the tumor suppressive roles of
ITLN1 in regulating the growth, migration, and invasion
of NB cells.
ITLN1 suppresses the growth and metastasis of NB cells
in vivo
We next investigated the efficacy of ITLN1 against
tumor growth and metastasis in vivo. Stable transfection
of ITLN1 into SH-SY5Y cells resulted in decreased
growth and tumor weight of subcutaneous xenograft tu-
mors in athymic nude mice, when compared to those
stably transfected with empty vector (mock) (Figure 5A
and B). In the experimental metastasis studies, SH-SY5Y
















































I3K/AKT signaling. (A) Western blot showing the phosphorylation of
nant ITLN1-treated SH-SY5Y (1 and 2 μg/ml for 24 hrs) and SK-N-BE(2)





























































































































































































































































































































































































































Figure 4 (See legend on next page.)
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Figure 4 ITLN1 suppresses the growth, migration, and invasion of NB cells in vitro through up-regulating NDRG2. (A and E) Western
blot showing the protein levels of ITLN1 [in culture supernatant (s)] and NDRG2 (in lysate) in NB cells stably transfected with empty vector (mock),
ITLN1, sh-Scb, or sh-ITLN1, and those co-transfected with sh-NDRG2 or NDRG2. (B and F) Quantification of colony formation assay showing the
growth potential of NB cells stably transfected with mock, ITLN1, sh-Scb, or sh-ITLN1, and those co-transfected with sh-NDRG2 or NDRG2.
(Cand G) Migration of NB cells upon transfection with mock, ITLN1, NDRG2, sh-Scb, sh-ITLN1, or sh-NDRG2 depicted by scratch assay after 24 hrs.
(D and H) Representation (top) and quantification (bottom) of matrigel invasion assay showing the in vitro invasion of NB cells stably transfected
with mock, ITLN1, sh-Scb, or sh-ITLN1, and those co-transfected with sh-NDRG2 or NDRG2. *P < 0.01 vs. mock or sh-Scb.
Li et al. Molecular Cancer  (2015) 14:47 Page 8 of 15fewer lung metastatic colonies than mock group
(Figure 5C). On the other hand, stable knockdown of
ITLN1 in SH-SY5Y cells resulted in increased growth and
tumor weight of subcutaneous xenograft tumors in athy-
mic nude mice (Figure 5D and E), and more lung meta-
static colonies (Figure 5F), than those stably transfected
with sh-Scb. These results are consistent with the findings
that ITLN1 suppresses the growth, migration, and inva-
sion of NB cells in vitro. Accordingly, identification of
NDRG2 as the target gene of ITLN1 may explain, at least
in part, why over-expression of ITLN1 suppresses the ag-
gressiveness of NB.
ITLN1 is under-expressed and inversely correlated with
NDRG2 in NB tissues and cell lines
To investigate the ITLN1 and NDRG2 expression in NB,
paraffin-embedded sections from 42 well-established pri-
mary cases were collected [20,21]. Immunohistochemical
staining revealed that ITLN1 was expressed in the tumor
cells of NB tissues (Figure 6A). ITLN1 expression was
detected in 14/42 (33.3%) cases and the staining was
weak in 6, moderate in 5, and intense in 3 (Additional
file 7: Table S1). The ITLN1 immunoreactivity was sig-
nificantly higher in NB cases with age less than 1 year
(P = 0.03), good differentiation (P < 0.001), lower mitosis
karyorrhexis index (MKI) (P = 0.002), and early INSS
stages (P = 0.003) (Additional file 7: Table S1). Notably,
the immunostaining of ITLN1 was associated with
NDRG2 immunoreactivity in NB cases (correlation co-
efficient R = 0.676, P < 0.001; Figure 6A and Additional
file 8: Table S2). Moreover, western blot and real-time
quantitative RT-PCR indicated lower expression levels of
ITLN1 and NDRG2 in subtotal 30 NB specimens and
cultured SK-N-SH, SK-N-AS, SH-SY5Y, and SK-N-BE(2)
cell lines, than those in normal dorsal ganglia (Figure 6B
and C). There was a positive correlation between ITLN1
and NDRG2 transcript levels in NB tissues (correlation
coefficient R = 0.827, P < 0.001, Figure 6D). Adminis-
tration of DNA methyltransferase inhibitor 5-aza-2′-
deoxycytidine (5-Aza-CdR) or pan histone deacetylase
inhibitor trichostatin A (TSA) resulted in slightly in-
creased ITLN1 transcript levels in NB cells (Additional
file 9: Figure S7). Kaplan–Meier survival plots of well-
defined NB cases derived from R2 microarray analysis
and visualization platform revealed that patients withhigh ITLN1 (P = 0.025) or NDRG2 (P = 0.0015) ex-
pression had greater survival probability than those with
low expression (Figure 6E). These results indicate that
ITLN1 is under-expressed and correlated with the
NDRG2 expression in NB tissues and cell lines.
Discussion
Human ITLN1 gene, locating at the chromosome 1q21.3
and encoding a glycoprotein consisting of 295 amino
acids and N-terminal signal peptide (18 amino acids),
was first isolated as the homolog of Xenopus oocyte
lectin XL35 from a small intestine cDNA library [22].
Previous studies have shown that ITLN1 is a soluble
protein detected in the culture supernatant of ITLN1-
transfected cells [9]. Interestingly, over-expression of
ITLN1 is identified in malignant pleural MPM by serial
analysis of gene expression [15]. Epithelioid-type MPMs,
but neither pleura-invading lung adenocarcinomas nor
reactive mesothelial cells near the lung adenocarci-
nomas, are positive for ITLN1 immunostaining, sugges-
ting that ITLN1 is a proper diagnostic marker for MPM
[14]. Quantitative proteomic techniques have also re-
vealed the value of ITLN1 as a useful proteomic tool for
risk stratification and prediction of poor outcome in
colorectal cancer [23]. Ectopic expression of ITLN1 into
prostate cancer cells results in significantly decreased
in vitro cell viability; meanwhile, increased tumori-
genicity and in vivo growth are observed in ITLN1
knockdown prostate cancer cells, indicating a tumor
suppressive role of ITLN1 in prostate cancer [24]. Re-
cent evidence shows that ITLN1 significantly inhibits
the proliferation and induces the apoptosis of hepatocel-
lular carcinoma cells, via decreasing p53 deacetylation in
a sirtuin 1-dependent manner [25]. These findings imply
the potential roles of ITLN1 in the development and
progression of human cancers. In the current study, we
demonstrated the down-regulation of ITLN1 in clinical
NB specimens, which was significantly associated with
clinicopathological features and patients’ survival. Since
administration of 5-Aza-CdR or TSA did not result in a
significant increase in ITLN1 transcript levels, we believe
that the epigenetic mechanisms are not likely to be
involved in the regulation of ITLN1 in NB cells. We
further confirmed that secretory ITLN1 inhibited the

































































































































Figure 5 (See legend on next page.)
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Figure 5 ITLN1 attenuates the growth and metastasis of NB cells in vivo. (A and D) Tumor growth curve of SH-SY5Y cells (1 × 106) stably
transfected with empty vector (mock), ITLN1, sh-Scb, or sh-ITLN1 in athymic nude mice (n = 5 for each group), after hypodermic injection for
4 weeks. (B and E) Representation (top) and quantification (bottom) of xenograft tumors formed by hypodermic injection of SH-SY5Y cells stably
transfected with mock, ITLN1, sh-Scb, or sh-ITLN1. (C and F) Representation (top, arrowhead) and quantification (bottom) of lung metastasis after
injection of SH-SY5Y cells (0.4 × 106) stably transfected with mock, ITLN1, sh-Scb, or sh-ITLN1 into the tail vein of athymic nude mice (n = 5 for
each group). **P < 0.001 vs. mock or sh-Scb.
Li et al. Molecular Cancer  (2015) 14:47 Page 10 of 15in vivo, suggesting the tumor suppressive roles of ITLN1
in NB.
NDRG2, a member of the N-Myc downstream-
regulated gene family, is down-regulated in many human
cancers, such as breast cancer [26], liver cancer [27], and
colorectal cancer [28], and exerts tumor suppressive
functions associated with cell growth, invasion and me-
tastasis [29]. Ectopic expression of NDRG2 inhibits the
tumor growth through inducing suppressor of cytokine
signaling 1 and subsequent inactivation of signal trans-
ducer and activator of transcription 3 in breast cancer
cells [30] or by attenuating the AP-1 activity in colon
carcinoma cells [31]. NDRG2 also inhibits the metastatic
potentials of breast cancer cells through inducing bone
morphogenetic protein 4 and subsequent suppression of
MMP-9 expression [17]. NDRG2 modulates the ad-
hesion and invasion of hepatocellular carcinoma cells
through regulating CD24 expression [32]. In addition,
NDRG2 suppresses the proliferation of breast cancer
cells by reducing VEGF expression [18]. In this study,
we demonstrated that NDRG2 was under-expressed in
NB specimens and associated with patients’ survival, and
NDRG2 suppressed the growth and aggressiveness of
cultured NB cells. Moreover, restoration of NDRG2 ex-
pression prevented the NB cells from ITLN1-mediated
changes in the growth, invasion, and metastasis, sug-
gesting that ITLN1 may exert its tumor suppressive
functions, at least in part, through up-regulating NDRG2
in NB.
KLF4 is a transcription factor that belongs to the
Krüppel family of zinc finger proteins, and exhibits both
oncogenic or tumor suppressive functions by interacting
with the binding elements on promoters of target genes
in different cellular contexts [33]. Tumor suppressive
functions of KLF4 have been established in several hu-
man cancers, including colon cancer, gastric cancer, and
bladder cancer [33]. KLF4 suppresses cell proliferation
and promotes apoptosis through inducing cell cycle ar-
rest at G1/S phase [34] and promoting p53-dependent
activation of p21Cip1 [35]. Meanwhile, oncogenic pro-
perties of KLF4 have been indicated as its ability
to reprogram fibroblast into pluripotent stem cells
in cooperation with POU class 5 homeobox 1, sex-
determining region Y-box 2, and c-Myc [36]. Previous
studies indicate that KLF4 is under-expressed in NB tis-
sues, and contributes to favorable disease outcome bydirectly mediating the growth and lineage determination
of NB cells [37]. It has been established that PI3K/AKT
signaling is required for the ubiquitination and degra-
dation of KLF4 [19], and inhibition of AKT activation by
PI3K inhibitor LY294002 stimulates the KLF4 expression
through reducing its ubiquitination [19]. Our data
showed that transcription factor KLF4 was crucial for
the NDRG2 expression in NB cells. In addition, we
found that ITLN1 induced the KLF4 expression via in-
activation of PI3K/AKT signaling, which was required
for ITLN1-mediated up-regulation of NDRG2 in NB
cells, suggesting the tumor suppressive roles of ITLN1/
KLF4/NDRG2 axis in the tumorigenesis of NB. Interes-
tingly, we noted the physical interaction between ITLN1
and glucose-regulated protein 78 (GRP78) in public
database BioGRID (http://thebiogrid.org/). GRP78 is an
endoplasmic reticulum lumenal protein that localizes to
the cell surface in cancer cells, and serves as a co-
receptor for growth and survival signaling [38,39]. Since
cell surface GRP78 forms complex with PI3K to promote
the production of phosphatidyl inositol-3,4,5-triphos-
phate (PIP3) and subsequent PI3K/AKT signaling [40],
we suspect that ITLN1 may modulate the PI3K/AKT sig-
naling through interacting with GRP78 and regulating
its activity in NB cells, which warrants our further
investigation.
Conclusions
In summary, for the first time, we have demonstrated
that ITLN1 is down-regulated in human NB, and se-
cretory ITLN1 efficiently inhibits the growth, invasion,
and metastasis of NB cells in vitro and in vivo through
up-regulating the expression of NDRG2. This study ex-
tends our knowledge about the regulation of tumor sup-
pressive genes associated with the progression of NB,
and suggests that ITLN1 may be of potential values as a
novel therapeutic target for NB.
Methods
Patient tissue samples
Approval to conduct this study was obtained from the
Institutional Review Board of Tongji Medical College
(approval number: 2011-S085). Paraffin-embedded speci-
mens from 42 well-established primary NB cases were
obtained from the Department of Pediatric Surgery,
Union Hospital of Tongji Medical College [20,21]. The
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Figure 6 (See legend on next page.)
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Figure 6 ITLN1 is under-expressed in NB tissues and cell lines. (A) Immunohistochemical staining showing the expression of ITLN1 and
NDRG2 in tumor specimens from 42 NB cases (arrowheads, brown). Scale bars: 100 μm. (B) Western blot showing the endogenous protein levels
of ITLN1 and NDRG2 in lysate from NB tissues (n = 30), NB cell lines, and normal dorsal ganglia (DG). (C) Endogenous transcript levels of ITLN1
and NDRG2 in NB tissues (n = 30), NB cell lines, and DG as detected by real-time quantitative RT-PCR. (D) Pearson’s coefficient correlation analysis
for the relationship between ITLN1 and NDRG2 transcript levels in NB tissues (n = 30). (E) Kaplan–Meier survival plots of well-defined NB patients with low
and high expression of ITLN1 or NDRG2, as derived from R2 microarray analysis and visualization platform (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
*P< 0.01 vs. DG.
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two pathologists. Based on the Shimada classification
system, including MKI, degree of neuroblastic differen-
tiation and stromal maturation, and patient’s age, 19 pa-
tients were classified as having favorable histology and
23 as having unfavorable histology. According to the
INSS, 7 patients were classified as stage 1, 7 as stage 2, 9
as stage 3, 11 as stage 4, and 8 as stage 4S. Fresh tumor
specimens were collected at surgery and stored at −80°C
until use. Protein and RNAs of normal human dorsal
ganglia were obtained from Clontech (Mountain View,
CA).Immunohistochemistry
Immunohistochemical staining was performed as previ-
ously described [20,21], with antibodies specific for ITLN1
(Abcam, Cambridge, MA; Santa Cruz Biotechnology,
Santa Cruz, CA; 1:200 dilutions) and NDRG2 (Santa Cruz
Biotechnology; 1:200 dilution). The negative controls in-
cluded parallel sections treated with omission of the pri-
mary antibody, in addition to an adjacent section of the
same block in which the primary antibody was replaced
by rabbit polyclonal IgG (Abcam Inc.) as an isotype con-
trol. The immunoreactivity in each tissue section was
assessed by at least two pathologists without knowledge of
the clinicopathological features of tumors. The degree of
positivity was initially classified according to the percen-
tage of positive tumor cells as the following: (−) < 5% cells
positive, (1+) 6–25% cells positive, (2+) 26–50% cells posi-
tive, and (3+) >50% cells positive.Western blot
Tissue or cellular protein was extracted with 1× cell lysis
buffer (Promega, Madison, WI). Culture supernatant
was concentrated using a 10,000 MWCO spin column
(Millipore, Billerica, MA). Protein expression in lysate or
supernatant was analyzed by western blot as previously de-
scribed [20,21,41-44], with antibodies specific for ITLN1,
NDRG2, VEGF, MMP-9, p-AKT (T308), p-AKT (S473),
AKT, KLF4, and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH, Santa Cruz Biotechnology). Enhanced
chemiluminescence substrate kit (Amersham, Piscataway,
NJ) was used for the chemiluminscent detection of signals
with autoradiography film (Amersham).Real-time quantitative RT-PCR
Total RNA was isolated with RNeasy Mini Kit (Qiagen
Inc., Valencia, CA). The reverse transcription reactions
were conducted with Transcriptor First Strand cDNA
Synthesis Kit (Roche, Indianapolis, IN). Real-time PCR
was performed with SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA) and primers listed
in Additional file 10: Table S3. The fluorescent signals
were collected during extension phase, Ct values of the
sample were calculated, and the transcript levels were
analyzed by 2-△△Ct method.
Cell culture
Human NB cell lines SK-N-SH (HTB-11), SK-N-AS (CRL-
2137), SH-SY5Y (CRL-2266), and SK-N-BE(2) (CRL-2271)
were purchased from American Type Culture Collection
(Rockville, MD). Cell lines were authenticated on the basis
of viability, recovery, growth, morphology, and isoenzymol-
ogy by the provider. Cell lines were used within 6 months
after resuscitation of frozen aliquots, and grown in
RPMI1640 medium (Life Technologies, Inc., Gaithersburg,
MD) supplemented with 10% fetal bovine serum (Life
Technologies, Inc.), penicillin (100 U/ml), and strepto-
mycin (100 μg/ml). Cells were incubated in serum-free
RPMI1640 for 4 hrs, and treated with recombinant ITLN1
protein (Enzo Life Sciences, Farmingdale, NY), LY294002
(Calbiochem, La Jolla, CA), 5-Aza-CdR (Sigma, St. Louis,
MO), or TSA (Sigma) as indicated.
Gene over-expression or knockdown
Human ITLN1 cDNA (942 bp) and KLF4 cDNA (1440)
were amplified from NB tissue (Additional file 11: Table S4),
and subcloned into pcDNA3.1 (Invitrogen, Carlsbad, CA).
The oligonucleotides encoding shRNA specific for ITLN1,
NDRG2, and KLF4 (Additional file 11: Table S4) were sub-
cloned into GV102 (Genechem Co., Ltd, Shanghai, China).
Stable cell lines were screened by administration of neo-
mycin (Invitrogen). The pcDNA3.1 and sh-Scb were ap-
plied as controls (Additional file 11: Table S4).
Luciferase reporter assay
The NDRG2 promoter luciferase reporter constructs
were kindly provided by Dr. Jian Zhang [45]. Tumor
cells were plated at 1 × 105 cells/well on 24-well plates,
and co-transfected with luciferase reporter vectors
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(10 ng, Promega). Twenty-four hrs post-transfection,
firefly and Renilla luciferase activity were consecutively
measured, according to the dual-luciferase assay manual
(Promega). For NDRG2 promoter activity, the luciferase
signal was normalized by firefly/Renilla ratio.
Rescue of target gene expression
Human NDRG2 expression vector was provided by
Dr. Victoria C. Foletta [46]. To restore the ITLN1-
induced up-regulation of NDRG2, stable cell lines were
transfected with the shRNA targeting the encoding re-
gion of NDRG2 (Additional file 11: Table S4) by Genesi-
lencer Transfection Reagent (Genlantis, San Diego, CA).
The NDRG2 expression vector was transfected into tumor
cells stably transfected with shRNA specific for ITLN1
(sh-ITLN1). The empty vector and sh-Scb were applied as
controls, respectively (Additional file 11: Table S4).
Chromatin immunoprecipitation
ChIP assay was performed according to the manufac-
turer’s instructions of EZ-ChIP kit (Upstate Biotechnology,
Temacula, CA) [41,44,47]. DNA was sonicated into frag-
ments of an average size of 200 bp. PCR primers were de-
signed targeting the binding site of KLF4 within NDRG2
promoter (Additional file 10: Table S3). Real-time qPCR
with SYBR Green PCR Master Mix was performed using
ABI Prism 7700 Sequence Detector. The amount of im-
munoprecipitated DNA was calculated in reference to a
standard curve and normalized to input DNA.
Cell viability assay
Tumor cells were cultured in 96-well plates at 5 × 103 cells
per well. Cell viability was monitored by the 2-(4,5-
dimethyltriazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT, Sigma) colorimetric assay [41,47]. All experiments
were done with 6–8 wells per experiment and repeated at
least three times.
Colony formation assay
Tumor cells were seeded at a density of 300 cells/ml on
35-mm dishes. Colony formation assay was performed
as previously described [43,47,48]. Positive colony for-
mation (more than 50 cells/colony) was counted. The
survival fraction of cells was expressed as the ratio of
plating efficiency of treated cells to that of control cells.
Scratch migration assay
To minimize cell proliferation, tumor cells were starved
in 0.5% serum medium, cultured in 24-well plates, and
scraped with the fine end of 1-ml pipette tips (time 0).
Plates were washed twice with phosphate buffered saline
to remove detached cells, and incubated with the com-
plete growth medium. Cell migration was photographedusing 10 high-power fields, at 0, 24 hr post-induction of
injury. Remodeling was measured as diminishing dis-
tance across the induced injury, normalized to the 0 hr
control, and expressed as outgrowth (μm) [21,41,42,49].
Cell invasion assay
Matrigel invasion assay was performed using membranes
coated with Matrigel matrix (BD Science, Sparks, MD).
To minimize the impacts of cell proliferation, homoge-
neous single cell suspensions (1 × 105 cells/well) were
starved in serum-free medium, added to the upper cham-
bers, and allowed to invade for 24 hrs at 37°C in a CO2 in-
cubator. Invaded cells were stained with 0.1% crystal violet
for 10 min at room temperature and examined by light
microscopy. Quantification of invaded cells was per-
formed according to published criteria [20,21,41-43,50].
In vivo growth and metastasis assay
All animal experiments followed the national guidelines
for the care and use of animals, and were approved by
the Animal Care Committee of Tongji Medical College
(approval number: Y20080290). For the in vivo tumor
growth studies, 2-month-old male nude mice (n = 5 per
group) were injected subcutaneously in the upper back
with 1 × 106 tumor cells. One month later, mice were
sacrificed and examined for tumor weight. The experi-
mental metastasis (0.4 × 106 tumor cells per mouse,
n = 5 per group) studies were performed with 2-month-
old male nude mice as previously described [20,21,44].
Statistical analysis
Unless otherwise stated, all data were shown as mean ±
standard error of the mean (SEM). The SPSS 18.0 statis-
tical software (SPSS Inc., Chicago, IL) was applied for
statistical analysis. The χ2 analysis and Fisher exact prob-
ability analysis were applied for comparison among the
expression of ITLN1, NDRG2, and individual clinico-
pathological features. Pearson’s coefficient correlation was
applied for analyzing the relationship between ITLN1 and
NDRG2 expression. The Kaplan-Meier method was used
to estimate survival rates, and the log-rank test was used
to assess survival difference. Difference of tumor cells was
determined by t test or analysis of variance (ANOVA).
Additional files
Additional file 1: Figure S1. Data mining in R2: microarray analysis and
visualization platform. (A) The ITLN1 transcript levels in different types of
normal and tumor tissues. (B) Over-lapping analysis showing six genes
significantly correlated with ITLN1 in colon cancer, lung cancer, renal
cancer, prostate cancer, and NB, including NDRG2, CCT3, DCUN1D5, ENO1,
MACF1, and PPM1G. (C) Pearson’s coefficient correlation analysis for the
relationship between ITLN1 and NDRG2 transcript levels in 88 well-defined
NB cases. (D) The ITLN1 and NDRG2 transcript levels in NB cases (n = 88)
with different INSS stages. *P < 0.05 vs. normal tissues.
Li et al. Molecular Cancer  (2015) 14:47 Page 14 of 15Additional file 2: Figure S2. Direct regulation of VEGF and MMP-9 by
NDRG2 in NB cells. (A) Western blot showing the expression of NDRG2,
VEGF, and MMP-9 in SH-SY5Y and SK-N-BE(2) cells transfected with empty
vector (mock) or NDRG2. (B) Western blot showing the expression of
VEGF and MMP-9 in NB cells stably transfected with mock or ITLN1, and
those co-transfected with sh-NDRG2.
Additional file 3: Figure S3. ITLN1 does not affect the expression of
other correlated genes. Real-time quantitative RT-PCR showing the
transcript levels of CCT3, DCUN1D5, ENO1, MACF1, or PPM1G in SH-SY5Y
and SK-N-SH cells stably transfected with empty vector (mock), ITLN1 (A),
sh-Scb, or sh-ITLN1 (B).
Additional file 4: Figure S4. Data mining of KLF4 in publicly available
tumor database. (A) Pearson’s coefficient correlation analysis for the
relationship between KLF4 and NDRG2 transcript levels in 88 NB
tissues derived from R2 microarray analysis and visualization platform.
(B) Kaplan–Meier survival plots of 88 NB patients with low or high
expression of KLF4 derived from R2 microarray analysis and visualization
platform.
Additional file 5: Figure S5. Restoration of NDRG2 expression in NB
cells. Real-time quantitative RT-PCR showing the transcript levels of ITLN1
and NDRG2 in NB cells stably transfected with empty vector (mock), ITLN1,
sh-Scb, or sh-ITLN1, and those co-transfected with sh-NDRG2 (A) or
NDRG2 (B). *P < 0.01 vs. mock or sh-Scb.
Additional file 6: Figure S6. ITLN1 suppresses the aggressiveness of
NB cells through up-regulating NDRG2. The sh-NDRG2 or NDRG2 was
transfected into NB cells stably transfected with empty vector (mock),
ITLN1, sh-Scb, or sh-ITLN1. The MTT colorimetric assay (A and D), colony
formation assay (B and E), and scratch assay (C and F) showing the
changes in cell viability, growth, and migration. *P < 0.01 vs. mock or
sh-Scb.
Additional file 7: Table S1. ITLN1 expression in human NB tissues.
Additional file 8: Table S2. Correlation between the expression of
ITLN1 and NDRG2.
Additional file 9: Figure S7. No epigenetic regulation of ITLN1 in NB
cells. Real-time quantitative RT-PCR showing the ITLN1 transcript levels in
NB cells treated with solvent (mock), 5-Aza-CdR (5 μmol/L, A), or TSA
(200 nmol/L, B) for 24 hrs.
Additional file 10: Table S3. Primer sets used for qPCR and ChIP.
Additional file 11: Table S4. Oligonucleotide sets used for constructs
and short hairpin RNAs.
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